Trial reportHuman psychopharmacology2017
Next-day residual effects of flibanserin on simulated driving performance in premenopausal women.
Trial report in Human psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- The Effects of Elinzanetant on Simulated Driving Performance in Healthy Women: A Randomized Phase I Study.Clinical and translational science · 2025Trial
- Effects of zuranolone on next-day simulated driving in healthy adults.Psychopharmacology · 2025Trial
- Residual effects of zopiclone on driving performance using a standardized driving simulator among healthy volunteers.Psychopharmacology · 2022Trial
- Validity and reliability of a driving simulator for evaluating the influence of medicinal drugs on driving performance.Psychopharmacology · 2021Trial
- Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls.Human psychopharmacology · 2020Trial
- An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine.Journal of clinical pharmacy and therapeutics · 2020Trial
- Next-day residual effects of flibanserin on simulated driving performance in premenopausal women.Human psychopharmacology · 2017Trial
- A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists.Exploratory research in clinical and social pharmacy · 2024Article
- Utilizing Technology to Enhance the Ecological Validity of Cognitive and Functional Assessments in Schizophrenia: An Overview of the State-of-the-Art.Schizophrenia bulletin open · 2024Article
- Response to Commentary by Spielmans.Sexual medicine · 2022Article
- Pharmacotherapy for Sexual Dysfunction in Women.Current psychiatry reports · 2022Review
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire.Neurology international · 2022Review
- Protocol for the development and validation of a driving simulator for evaluating the influence of drugs on driving performance.Medicine · 2019Article
- Evaluation and Management of Hypoactive Sexual Desire Disorder.Sexual medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to determine the next-day residual effects of acute and steady-state nighttime dosing of flibanserin on simulated driving performance and cognitive function in healthy premenopausal women.
methodsIn this randomized, double-blind, placebo-controlled, four-way crossover study, 72 subjects were treated with either acute oral doses of placebo, zopiclone 7.5 mg (positive control) or flibanserin 100 mg at bedtime (indicated therapeutic dose), or after chronic nightly oral doses of flibanserin 100 mg for 1 week followed by a single bedtime dose of flibanserin 200 mg (supratherapeutic dose). Simulated driving assessments were conducted 9 hr after dosing and cognitive function tests were administered immediately before or during the driving assessment.
resultsZopiclone increased standard deviation of lateral position (≥3.1 cm; p < .0001) relative to placebo and impaired other parameters previously shown to be sensitive to sedation. No impairment was detected for flibanserin at either dose relative to placebo. Flibanserin 200 mg was similar to the 100-mg dose on cognitive testing and driving performance even though commonly reported adverse events for flibanserin were predictably increased at the higher dose.
conclusionsAt both therapeutic and supratherapeutic doses, flibanserin did not impair next-day driving performance and cognitive function compared to placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.